Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop

Controlled Clinical Trials

Volumn 22, Issue 5, 2001, Pages 485-502

  De Gruttola, Victor G ^a   Clax, Pamela ^b   DeMets, David L ^c   Downing, Gregory J ^d   Ellenberg, Susan S ^e   Friedman, Lawrence ^f   Gail, Mitchell H ^g   Prentice, Ross ^h   Wittes, Janet ⁱ   Zeger, Scott L ^j  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ University of Iowa   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Biomarkers; Meta analysis; Surrogate endpoints

Indexed keywords

ANTIRETROVIRUS AGENT; BIOCHEMICAL MARKER; CD4 ANTIGEN; NELFINAVIR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DATA BASE; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; EVALUATION; GENOME; HEALTH CARE ORGANIZATION; HUMAN; MATHEMATICAL ANALYSIS; META ANALYSIS; METHODOLOGY; PERSONNEL; PREDICTION; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL; T LYMPHOCYTE; TECHNOLOGY; TRAINING; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TRANSMISSION; WORKSHOP;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOTECHNOLOGY; CLINICAL TRIALS; CONSENSUS DEVELOPMENT CONFERENCES; DISEASE TRANSMISSION, VERTICAL; FEMALE; GENOMICS; HIV INFECTIONS; HIV-1; HUMANS; META-ANALYSIS; NATIONAL INSTITUTES OF HEALTH (U.S.); PREDICTIVE VALUE OF TESTS; PREGNANCY; RESEARCH DESIGN; RNA, VIRAL; UNITED STATES; VIRAL LOAD; ZIDOVUDINE;

EID: 0034802767     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(01)00153-2     Document Type: Conference Paper

References (18)

1. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
2. Surrogate endpoints in clinical trials: Definition and operational criteria
3. Statistical validation of intermediate endpoints for chronic diseases
4. Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS
5. Meta-analysis for the evaluation of potential surrogate markers
6. Surrogate end points in clinical trials: Are we being misled?
7. Estimating the proportion of treatment effect explained by a surrogate marker
8. Perspective: Validating surrogate markers - Are we being naive?
9. The validation of surrogate endpoints in meta-analyses of randomized experiments
10. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research
11. HIV-1-dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
12. Decay characteristics of HIV-1 infected compartments during combination therapy
13. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics
14. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant
15. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial
16. On meta-analytic assessment of surrogate outcomes
17. The joint analysis of longitudinal data comprising repeated measures and times-to-events